Transparency in Medicines Regulatory Affairs Reclaiming Missed Opportunities

South African Journal of Bioethics and Law 10 (2):69-74 (2017)
  Copy   BIBTEX

Abstract

Transparency is a salutary value in our constitutional architecture. It has also been described as a necessary element in promoting accountability in the regulatory aspects of essential medicines. Despite its several incarnations, the Medicines and Related Substances Act (Medicines Act) retains a provision headed 'Preservation of secrecy' (section 34). This contributionseeks to evaluate section 34 in the context of transparency and ascertain whether it is in conflict with other legislation pertaining to the promotion of access to information and, in particular, whether it is consistent with the Constitution of the Republic of South Africa.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,783

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Supply of medicines: paternalism, autonomy and reality.D. Prayle & M. Brazier - 1998 - Journal of Medical Ethics 24 (2):93-98.
Trade Rules, Intellectual Property, and the Right to Health.Lisa Forman - 2007 - Ethics and International Affairs 21 (3):337-357.
Transparency, Interrupted.Clare Birchall - 2011 - Theory, Culture and Society 28 (7-8):60-84.
GlaxoSmithKline and Access to Essential Medicines (B).N. Craig Smith & Anne Duncan - 2005 - Journal of Business Ethics Education 2 (1):123-132.
Transparency: The Key to Better Governance?Christopher Hood & David Heald - unknown - Proceedings of the British Academy 135.

Analytics

Added to PP
2018-06-07

Downloads
8 (#1,315,307)

6 months
3 (#969,763)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references